| "-tuzu-" (tumor com a objectiu) |
Alemtuzumab, Bevacizumab/Ranibizumab, Bivatuzumab mertansina, Cantuzumab mertansina, Dacetuzumab, Etaracizumab, Etaratuzumab, Gemtuzumab ozogamicina, Inotuzumab ozogamicin, Labetuzumab, Lintuzumab, Matuzumab, Nimotuzumab, Pertuzumab, Sibrotuzumab, Sontuzumab, Tacatuzumab tetraxetan, Trastuzumab, Tucotuzumab celmoleukin |
| "-lizu-" (sistema immunitari com a objectiu) |
Aselizumab, Atlizumab, Apolizumab, Cedelizumab, Certolizumab pegol, Daclizumab, Eculizumab, Efalizumab, Epratuzumab, Erlizumab, Fontolizumab, Ibalizumab, Lebrilizumab, Mepolizumab, Natalizumab, Ocrelizumab, Omalizumab, Pascolizumab, Pexelizumab, Reslizumab, Rovelizumab, Ruplizumab, Siplizumab, Talizumab, Teplizumab, Tocilizumab, Toralizumab, Visilizumab |
